Pharma

Your Article Summary

See Latest Articles

Primary Endpoint Achieved in Phase III Clinical Trial of Epogin in Chemotherapy Induced Anemia
Chugai Pharmaceutical Co., 08/31/09

Chugai Pharmaceutical Co., Ltd. announced that Phase III study of the recombinant human erythropoietin "Epogin Injection" achieved the primary endpoint by significantly reducing the theoretical transfusion rate in patients with chemotherapy induced anemia.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology, 12/09/09

The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury
Trials, 12/09/09

Umbilical vein oxytocin for the treatment of retained placenta (Release Study): a double-blind, randomised controlled trial
The Lancet - Early Online Publication, 12/09/09

 See all of Drug Trials